A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

By sjmartinez • February 7, 2024

Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 6;15(1):974. doi: 10.1038/s41467-024-44905-z. PMID: 38321023.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]

Pulmonary Rehabilitation Referral Practice Patterns Across Lung Transplantation Centers in the United States: A Multicenter Survey-Based Study

Deleija JD, Shah SZ, Felzer J, Tan X, Garvey C, DeCato TW, Pennington K, Sehgal S, Kennedy C, Kumar A. Pulmonary Rehabilitation Referral Practice Patterns[...]

Cardiovascular Outcomes in Patients With Cancer Undergoing Cardiac Implantable Electronic Device Implantation

Krishan S, Agarwal S, Munir MB, Ajijola O, Yang EH, Deswal A, Torbey E, Cheng R, Asad ZUA. Cardiovascular Outcomes in Patients With Cancer Undergoing[...]